Thus, in a pre-leukemic setting, mutation of Cebpa leads to increased HSC proliferation but its impact on HSC function was obscured by transformation to AML [22] and in a fetal setting, E.14.5 LSK cells were reported to have a competitive advantage although their proliferative status was unaltered [21]. Here, CEBPA is linked to acute myeloid leukemia.